ライフサイエンスコーパス: nephrectomy

1 ars (before nephrectomy, 1 and 2 years after nephrectomy).

2 erval [95% CI], 0.26 to 0.43, versus radical nephrectomy).

3 WT mice and in rats with CKD due to subtotal nephrectomy.

4 nagement, and ultimately requiring allograft nephrectomy.

5 noma at high risk for tumor recurrence after nephrectomy.

6 ransplantation was performed after recipient nephrectomy.

7 91%]) gained clinical benefit before planned nephrectomy.

8 stic risk, geographical region, and previous nephrectomy.

9 on to those persons willing to undergo donor nephrectomy.

10 and attributable to surgical issues of donor nephrectomy.

11 ed informed consent procedure for live donor nephrectomy.

12 d LOS and decreased narcotic use after donor nephrectomy.

13 inuria and glomerulosclerosis after subtotal nephrectomy.

14 hemia reperfusion, followed by contralateral nephrectomy.

15 d tubulointerstitial fibrosis after subtotal nephrectomy.

16 renal cell carcinoma who had also undergone nephrectomy.

17 eral complications solely after living donor nephrectomy.

18 including aorta and lung, after 5/6 subtotal nephrectomy.

19 ining nontransplanted kidney of donors after nephrectomy.

20 collagen in aorta of mice after 5/6 subtotal nephrectomy.

21 renal function outcomes compared to radical nephrectomy.

22 oach in selected patients undergoing partial nephrectomy.

23 in nephrovascular toxins, IS and PCS, after nephrectomy.

24 fects of prolonged clamp time during partial nephrectomy.

25 ion through donor assessment to actual donor nephrectomy.

26 events in patients long after their radical nephrectomy.

27 e laparoscopic approach for left-sided donor nephrectomy.

28 ltimate postoperative function after partial nephrectomy.

29 , with similar oncologic outcomes to radical nephrectomy.

30 ctional outcomes after ischemia-free partial nephrectomy.

31 traditional multiple-port laparoscopic donor nephrectomy.

32 LKT) after retroperitoneoscopic living-donor nephrectomy.

33 ant percentage of patients following partial nephrectomy.

34 n) followed by reperfusion and contralateral nephrectomy.

35 p ischemia in 40 patients undergoing partial nephrectomy.

36 t have an increased risk of recurrence after nephrectomy.

37 minimize renal functional loss after partial nephrectomy.

38 cardiomyopathy in mice subjected to partial nephrectomy.

39 filtration rate (SNGFR) following unilateral-nephrectomy.

40 nt to that reported after radical or partial nephrectomy.

41 evaluation, well before scheduling the donor nephrectomy.

42 90 days (HR = 1.84, 95% CI: 1.02-3.32) after nephrectomy.

43 90 days (HR = 2.23, 95% CI: 1.51-3.29) after nephrectomy.

44 ors developed hypertension within 2 years of nephrectomy.

45 -1 in healthy and uremic rats induced by 5/6 nephrectomy.

46 A total of 123 patients (23%) had delayed nephrectomy.

47 renal failure, adenine diet induced and 5/6 nephrectomy.

48 mplications were observed in 14 (22%) of the nephrectomies.

49 d deceased kidney donors and normal poles of nephrectomies.

50 pertrophy was induced by progressive partial nephrectomies.

51 ompared with all previous laparoscopic donor nephrectomies.

52 hort of 100 multiple-port laparoscopic donor nephrectomies.

53 nter experience with 1300 laparoscopic donor nephrectomies.

54 BNE) and early (4-15 months; EBNE) bilateral nephrectomies.

55 990 and 12/31/2014, we did 2002 living donor nephrectomies.

56 and followed up annually for 2 years (before nephrectomy, 1 and 2 years after nephrectomy).

57 partial nephrectomy (35%), unilateral total nephrectomy (10.5%), unilateral partial nephrectomy (4%)

58 omy; 20802, total nephrectomy; 8060, partial nephrectomy; 134985, hysterectomy; and 27445, oophorecto

59 %) total nephrectomies, 2759 (34.2%) partial nephrectomies, 14 047 (10.4%) hysterectomies, and 1782 (

60 artial nephrectomy (4%), and bilateral total nephrectomies (2.5%).

61 ) radical prostatectomies, 1405 (6.8%) total nephrectomies, 2759 (34.2%) partial nephrectomies, 14 04

62 partial nephrectomy (48%), bilateral partial nephrectomy (35%), unilateral total nephrectomy (10.5%),

63 otal nephrectomy (10.5%), unilateral partial nephrectomy (4%), and bilateral total nephrectomies (2.5

64 total nephrectomy with contralateral partial nephrectomy (48%), bilateral partial nephrectomy (35%),

65 al mice and mice that had undergone subtotal nephrectomy (5/6 Nx), a mouse model of CKD.

66 ssable for clinical benefit prior to planned nephrectomy; 80 of 104 (76.9%) were men; median [interqu

67 nderwent radical prostatectomy; 20802, total nephrectomy; 8060, partial nephrectomy; 134985, hysterec

68 Kidney function decreased by 30% after nephrectomy (absolute change estimated glomerular filtra

69 means [95% CI]: 1.47 [1.12, 1.93]) and open nephrectomy (adjusted ratio of means [95% CI]: 2.61 [1.0

70 Conclusions and Relevance: Nephrectomy after upfront pazopanib therapy could be per

71 stages III and IV) clear cell RCC treated by nephrectomy; after exclusion of 59 (39%) overweight pati

72 0%, which remained elevated at 2 years after nephrectomy (all P<0.001).

73 y low-risk criteria can be safely managed by nephrectomy alone with resultant reduced exposure to che

74 e 4 and higher) CKD after radical or partial nephrectomy among veterans treated for kidney cancer in

75 Very early bilateral nephrectomies and documentation of severe hypotensive ep

76 s (VED, onset <= 3 months) without bilateral nephrectomies and patients with total kidney volumes (TK

77 de H3K36me3 profiles from four cytoreductive nephrectomies and SETD2 isogenic renal cell carcinoma (R

78 alone), recipients of simultaneous bilateral nephrectomies and transplant (simultaneous), and recipie

79 ents were referred for transplant having had nephrectomies and were ultimately not transplanted.

80 the use of nephron-sparing surgery (partial nephrectomy and ablation) increased (from 21.5% to 49.0%

81 two experimental rat models of CKD (subtotal nephrectomy and adenine diet) which show early insulin r

82 ents with reduced GFR, as some causes (e.g., nephrectomy and aging) appear to be associated with a re

83 tomy only and a control group undergoing 5/6 nephrectomy and complete omentectomy.

84 panib therapy prior to planned cytoreductive nephrectomy and continued pazopanib therapy after surger

85 In 45 rats AKI was induced by right nephrectomy and contralateral clamping of the renal pedi

86 on of collectrin is increased after subtotal nephrectomy and during high-salt feeding, raising the qu

87 c VSMCs increased in mice after 5/6 subtotal nephrectomy and in mice producing human angiopoietin-2.

88 ntermediate or high risk of recurrence after nephrectomy and is the appropriate control of our curren

89 fits of nephron sparing surgery over radical nephrectomy and its oncologic equivalency confirmed, the

90 the current advantages of laparoscopic donor nephrectomy and may continue to decrease disincentives t

91 were randomly assigned, stratified by prior nephrectomy and Memorial Sloan-Kettering Cancer Center p

92 Recipients underwent bilateral nephrectomy and orthotopic renal transplantation (day 0)

93 Lewis rats underwent bilateral nephrectomy and received an orthotopic Dark Agouti renal

94 ce and highlight emerging issues for partial nephrectomy and renal function.

95 long-term oncological equivalence to radical nephrectomy and renal functional benefit, partial nephre

96 similar observations in rats after subtotal nephrectomy and tested whether pharmacologic inhibition

97 he fecal samples of rats 6 weeks after 5/6th nephrectomy and those of sham-operated rats, still sugge

98 its role in a CKD model (involving subtotal nephrectomy) and a hypertension model (induced by angiot

99 Male C57BL/6 mice underwent 5/6 nephrectomy, and 8 weeks later, they were subjected to L

100 2 nonsmokers who underwent a renal biopsy or nephrectomy, and in CS-exposed mice, we assessed patholo

101 he cohort that did and did not undergo donor nephrectomy, and performed simple linear logistic regres

102 Over 5,000 living kidney donor nephrectomies are performed annually in the US.

103 ify risk of clinically significant CKD after nephrectomy are needed.

104 preliminary results of zero ischemia partial nephrectomy are promising, further research is needed to

105 techniques for minimally invasive live donor nephrectomy are safe and associated with low complicatio

106 onstrate that the majority of T1b/T2 partial nephrectomy are still carried out by open surgery, and c

107 ng born with two kidneys and then undergoing nephrectomy are unclear.

108 ions of renal transplants after living donor nephrectomy are uncommon.

109 physiological changes that occur early after nephrectomy are well documented, less is known about the

110 ses is transforming with adoption of partial nephrectomy as a safe and feasible surgical option with

111 ed laparoscopic and robotic-assisted partial nephrectomy as a safe management option for pathologic T

112 e," "complications," and "laparoscopic donor nephrectomy" as keywords.

113 has become the gold standard for live-donor nephrectomy, as it results in a short convalescence time

114 Subsequent rates of documented infection and nephrectomy, as well as patient survival, were ascertain

115 In propensity score-matched cohorts, partial nephrectomy associated with a significantly lower relati

116 of renal transplant alone patients required nephrectomy at 10 years follow-up.

117 ) TSC patient had a left followed by a right nephrectomy at ages 24 and 27.

118 fter hand-assisted laparoscopic living donor nephrectomy at our institution from January 2008 to Febr

119 ell renal cell carcinoma who had undergone a nephrectomy at the Cleveland Clinic (OH, USA).

120 on that was intact versus impaired (from 3/4 nephrectomy), before and after additional impairment (fr

121 Timing of bilateral nephrectomy (BN) is controversial in patients with refra

122 ond (male) TSC patient had bilateral partial nephrectomies (both at age 36), with similar findings of

123 ney function, from baseline at 2 years after nephrectomy (both P<0.03).

124 Single-port donor nephrectomy can be integrated as a standardized approach

125 Simultaneous bilateral nephrectomy can be safely performed at the time of renal

126 Model systems demonstrate that nephrectomy can precipitate hypertrophic podocyte stress

127 murine model in which CKD is induced by 5/6 nephrectomy (CKD mice), we observed defects in glucose-s

128 The role of cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRC

129 e kinase inhibitors (TKIs) and cytoreductive nephrectomy (CN) in patients with metastatic renal cell

130 Subtotal nephrectomy created a mouse model of CKD with BUN >80 mg

131 rescence microscopy performed on nondiseased nephrectomy cryosections from persons with normal kidney

132 Use of radical nephrectomy decreased over time (from 69.0% to 42.5%), a

133 and systematic reviews suggest that partial nephrectomy decreases the risks of adverse renal functio

134 e-third of organ-confined cancers treated by nephrectomy develop metastasis during follow-up care.

135 imally invasive surgical approaches to donor nephrectomy (DN) has been driven by the potential advant

136 years was longer than for radical or partial nephrectomy, especially for patients at higher risk (Cha

137 Many strategies regarding timing of native nephrectomies exist for patients with symptomatic polycy

138 Post-donor nephrectomy follow-up consisted of standard questionnair

139 Male mice underwent a unilateral (right) nephrectomy followed by 30 minutes of contralateral (lef

140 blished series of minimally invasive partial nephrectomies for such renal masses.

141 s a paucity of data for laparoscopic partial nephrectomies for this larger tumor size.

142 we studied patients who underwent a radical nephrectomy for a tumor.

143 lt patients had undergone partial or radical nephrectomy for histologically confirmed ccRCC and fell

144 Partial nephrectomy for larger kidney tumors (T1b) has gained wi

145 here is an increased push to perform partial nephrectomy for larger tumors.

146 in a prospective cohort of patients who had nephrectomy for localised RCC at MSK.

147 Complex partial nephrectomy for multiple renal tumors, or multiplex part

148 asibility of performing laparoscopic partial nephrectomy for renal tumors 4-7 cm in size has clearly

149 Radical nephrectomy for SRMs should only be reserved for patient

150 To review current status of partial nephrectomy for treatment of T1b and T2 renal mass, focu

151 ma from 812 patients who underwent a radical nephrectomy (for a tumor), separately characterizing glo

152 recent clinical trial of partial and radical nephrectomy found minimal differences in survival or adv

153 tween 2000 and December 2013, 106 live donor nephrectomies from anonymous living-donors were performe

154 over ischemia time in impacting post-partial nephrectomy function.

155 The first case underwent a radical nephrectomy given the central location of the tumor and

156 Finally, patients treated with a partial nephrectomy had reduced risk of mortality (hazard ratio,

157 ction after hand-assisted laparoscopic donor nephrectomy (HALDN) confers significant morbidity to a h

158 Hand-assisted retroperitoneoscopic donor nephrectomy (HARP) is an alternative approach, combining

159 of hand-assisted retroperitoneoscopic donor nephrectomy (HARP).

160 Minimally invasive live donor nephrectomy has become a fully implemented and accepted

161 o-ischemia, approach to laparoscopic partial nephrectomy has been a proposed means of preserving glob

162 tion of minimal invasive, laparoscopic donor nephrectomy has increased live kidney donation, paving t

163 -clamp technique during laparoscopic partial nephrectomy has variably shown increased intraoperative

164 Laparoscopic and robotic-assisted partial nephrectomy have been widely adopted for the management

165 Submitted delayed nephrectomy histology showed anaplasia (n = 8; excluded

166 In addition, prior transplant nephrectomy (HR 2.04 [1.00-4.17], P = .0495) was also as

167 s for kidney transplantation were unilateral nephrectomy (HR 4.2, 95% CI 2.3-7.7), ifosfamide (24.9,

168 al prostatectomy, total nephrectomy, partial nephrectomy, hysterectomy, or oophorectomy at 1370 hospi

169 ly, and most would be motivated toward donor nephrectomy if offered a payment of $50000.

170 cautious indication of very early bilateral nephrectomies in ARPKD, especially in patients with resi

171 To test the association between bilateral nephrectomies in patients with autosomal recessive polyc

172 (managed with repeat NSS in 6 and completion nephrectomy in 1) and 3 had an episode of intestinal obs

173 We changed our approach to single-port donor nephrectomy in 2009 and have compared outcomes with trad

174 Uremia was induced by 5/6 nephrectomy in adult female mice.

175 s ascites is a rare complication after donor nephrectomy in experienced centers.

176 of robotic-assisted surgery only for partial nephrectomy in facilities with medium-high (1.67 [1.13-2

177 The rate of nephrectomy in follow-up was lower in donors versus nond

178 CRD was induced by 5/6 nephrectomy in high-fat high-cholesterol fed apolipoprot

179 The likelihood of tumour recurrence after nephrectomy in localised clear cell renal cell carcinoma

180 led this condition by inducing CKD via 5/6th nephrectomy in mice.

181 h established kidney damage, the effect of a nephrectomy in non-chronic kidney disease patients is no

182 The role of partial nephrectomy in nonelective treatment of T2 tumors is mor

183 e of nephron-sparing surgery exceeds radical nephrectomy in patients who receive surgery.

184 titutional series indicate that open partial nephrectomy in patients with a solitary kidney can achie

185 Importance: The role of cytoreductive nephrectomy in patients with metastatic renal cancer in

186 rmine the long-term risk of partial or total nephrectomy in previous living kidney donors compared to

187 ont pazopanib therapy prior to cytoreductive nephrectomy in previously untreated patients with metast

188 renal functional benefit compared to radical nephrectomy in select patients.

189 is becoming an alternate standard to radical nephrectomy in the management of T1b tumors.

190 grams must weigh risks of performing a donor nephrectomy in those with 2 APOL1 renal risk variants (h

191 To determine if observation alone after nephrectomy in very low-risk Wilms tumor (defined as sta

192 , 0.15; 95% CI, 0.11 to 0.19, versus radical nephrectomy) in propensity score-matched cohorts.

193 ecent studies suggest that GFR loss at donor nephrectomy increases the risk of eventual end-stage ren

194 Partial nephrectomy induced cardiomyopathy and anemia in the mic

195 eceptor-deficient mice were subjected to 5/6 nephrectomy, irradiated, and transplanted with bone marr

196 Informed consent in live donor nephrectomy is a topic of great interest.

197 Adaptive hyperfiltration after donor nephrectomy is attributable to hyperperfusion and hypert

198 ectomy and renal functional benefit, partial nephrectomy is becoming an alternate standard to radical

199 or these patients, the role of cytoreductive nephrectomy is disputed.

200 te superior functional outcomes when partial nephrectomy is performed without global ischemia, even a

201 we show that kidney transplantation "reverse nephrectomy" is also associated with podocyte hypertroph

202 jury, many studies have suggested that donor nephrectomy itself does not cause long-term loss of GFR

203 Post-partial nephrectomy kidney quantity and quality are surgically n

204 Compared with mini-incision open donor nephrectomy, laparoscopic donor nephrectomy (LDN) is con

205 After a radical nephrectomy, larger nephrons and nephrosclerosis predict

206 Laparoscopic donor nephrectomy (LDN) has become the gold standard for live-

207 n open donor nephrectomy, laparoscopic donor nephrectomy (LDN) is considered cost-effective.

208 y rare complication after laparoscopic donor nephrectomy (LDN).

209 Subtotal nephrectomy led to insulin resistance and dyslipidemia i

210 1Nx-0) after partial (LR-partial) or radical nephrectomy (LR-radical) or as moderate/high risk (M/HR;

211 The five donor nephrectomies made nine kidney transplantations possible

212 atic RCC, with a clear cell component, prior nephrectomy, measurable disease, and 0 or 1 prior therap

213 inhibition by dimethylthiourea (DMTU) in 5/6 nephrectomy mice.

214 or higher after radical (n=9759) or partial nephrectomy (n=4370) was 7.9% overall.

215 Furthermore, in those who had nephrectomy of the first allograft, class 2 repeated mis

216 Partial nephrectomy of the left kidney was performed.

217 rimental transplantation model used included nephrectomy of the remaining native kidney at d 5 post-t

218 or in our cohort received a partial or total nephrectomy of their remaining kidney during our follow-

219 e short- and long-term effects of unilateral nephrectomy on living donors have been important conside

220 f rats: an experimental group undergoing 5/6 nephrectomy only and a control group undergoing 5/6 neph

221 Notably, children who undergo nephrectomy or adults who serve as kidney donors exhibit

222 In mice subjected to 5/6 subtotal nephrectomy or unilateral ureteral obstruction, plasma l

223 In conclusion, compared with radical nephrectomy, partial nephrectomy was associated with a m

224 s who underwent radical prostatectomy, total nephrectomy, partial nephrectomy, hysterectomy, or oopho

225 wards improved kidney function after partial nephrectomy, particularly for larger tumors.

226 After nephrectomy, patients were followed without adjuvant che

227 verview of outcomes for laparoscopic partial nephrectomies performed with or without hilar clamping f

228 severe renal autoregulation impairment (3/4 nephrectomy plus amlodipine), renal blood flow in consci

229 l ischemia-reperfusion injury and unilateral nephrectomy plus contralateral ischemia-reperfusion inju

230 tives were to compare outcomes after partial nephrectomy (PN) and radical nephrectomy (RN) from the N

231 Partial nephrectomy (PN) for SRMs is the standard treatment that

232 A shift towards partial nephrectomy (PN) in the management of small renal cell c

233 (<=4 cm) renal tumors versus routine partial nephrectomy (PN), accounting for various competing cause

234 tal uremic cardiomyopathy induced by partial nephrectomy (PNx).

235 and recipients with pretransplant bilateral nephrectomies (pre).

236 tors such as blood transfusion and allograft nephrectomy, prolonged immunosuppression withdrawal rema

237 regant properties of HDL, we used a CKD (5/6 nephrectomy) rabbit model.

238 FGFR4 attenuates established LVH in the 5/6 nephrectomy rat model of CKD.

239 One possibility is that ESRD is due to the nephrectomy-related reduction in GFR, followed by an age

240 eir evolution and promising results, partial nephrectomy remains the cornerstone of surgical treatmen

241 ell carcinoma (RCC) after radical or partial nephrectomy remains unknown, and evidence to support cur

242 Cases were separated into those requiring nephrectomy, renorrhaphy, or endovascular repair based o

243 multiple renal tumors, or multiplex partial nephrectomy, requires not only exceptional surgical skil

244 Compared with sham operation, nephrectomy resulted in significant increases in urea an

245 s after partial nephrectomy (PN) and radical nephrectomy (RN) from the National Cancer Database (NCDB

246 We also fully segmented 15 nephrectomy samples and calculated the network's glomeru

247 k for multiclass segmentation of PAS-stained nephrectomy samples and transplant biopsies.

248 In a screen of nephrectomy samples from 56 patients with RCC, we found

249 WT nephrectomy samples from 586 SIOP WT 2001 patients were

250 e network detected 92.7% of all glomeruli in nephrectomy samples, with 10.4% false positives.

251 We also studied human nephrectomy samples.

252 Mice that have undergone partial nephrectomy serve as an experimental model of uremic car

253 2 at cancer treatment centers with access to nephrectomy services.

254 with such masses minimally invasive partial nephrectomy should be considered for elective and absolu

255 Partial nephrectomy should remain the standard of care for small

256 pression after transplant failure, and graft nephrectomy, showed that AMS (odds ratio [OR]: 1.44 per

257 Unilateral nephrectomy significantly decreased glomerular filtratio

258 Compared with multiple-port donor nephrectomy, single-port patients had similar operative

259 ransglutaminase isozymes in the rat subtotal nephrectomy (SNx) model of progressive renal scarring.

260 Adriamycin nephrotoxicity and subtotal nephrectomy (SNx) studies indicated that deletion of the

261 K181-V182 and mAbprostasin) to examine human nephrectomy specimens.

262 ical refinements, such as anatomical partial nephrectomy surgery.

263 noma at high risk for tumor recurrence after nephrectomy, the median duration of disease-free surviva

264 veness of partial nephrectomy versus radical nephrectomy to preserve kidney function has not been wel

265 methylcholanthrene sarcoma, and 5/6 subtotal nephrectomy) to evaluate efficacy of TCMCB07, a syntheti

266 vity (>/= 1+ by immunohistochemistry) in his nephrectomy tumor specimen.

267 d, diabetes mellitus, preoperative eGFR, and nephrectomy type (partial/radical)-to fit logistic regre

268 We used db/db mice with early unilateral nephrectomy (Unx) as a murine model of progressive DN an

269 In rats subjected to unilateral nephrectomy (UNx), we examined cardiac electrophysiologi

270 reduction, mice were subjected to unilateral nephrectomy (UNx).

271 diate renal hypertrophy following unilateral nephrectomy (UNX).

272 80 renal transplantations after living donor nephrectomy, ureteral complications occurred in 18 (3.7%

273 The comparative effectiveness of partial nephrectomy versus radical nephrectomy to preserve kidne

274 on (eGFR>/=60 ml/min per 1.73 m(2)), partial nephrectomy was also associated with a significantly low

275 , compared with radical nephrectomy, partial nephrectomy was associated with a marked reduction in th

276 7.6 years, maximum 21.0 years), the rate of nephrectomy was not statistically different in donors ve

277 cations occurred in 142 patients (9.7%), and nephrectomy was performed in 124 (8.8%).

278 metric analysis of glomeruli obtained during nephrectomy was performed in 19 subjects.

279 Nephrectomy was performed in 63 (61%) of patients; 14 (2

280 Allograft nephrectomy was performed in 81% of hospitalized patient

281 Nephrectomy was performed in UT-A1/A3 knockout (UT-KO) t

282 ctive antibody significantly increased after nephrectomy was performed.

283 dney injury can initiate in the donor before nephrectomy, we tested the hypothesis that anaphylatoxin

284 KD in rats by an adenine-rich diet or by 5/6 nephrectomy; we also used AhR(-/-) knockout mice overloa

285 tage I favorable histology Wilms tumors with nephrectomy weight <550g and age at diagnosis <2 years)

286 Rats with subtotal nephrectomies were lethally irradiated and underwent sal

287 All living-donor nephrectomies were performed by retroperitoneoscopic app

288 Nephrectomies were preferentially performed on the left

289 ications after minimally invasive live donor nephrectomy were included.

290 e-risk Wilms' tumours assessed after delayed nephrectomy were randomly assigned (1:1) by a minimisati

291 ferral centers, donors undergoing left-sided nephrectomy were randomly assigned to HARP or LDN.

292 kidneys or a solitary kidney from unilateral nephrectomy who underwent contrast material-enhanced com

293 living kidney donors frequently ask whether nephrectomy will affect their future pregnancies.

294 compared outcomes from 135 single-port donor nephrectomies with an immediately preceding cohort of 10

295 only 3 patients (7.1%) underwent unilateral nephrectomy with contralateral NSS.

296 rgical approaches included: unilateral total nephrectomy with contralateral partial nephrectomy (48%)

297 Transplant nephrectomy with cystectomy was performed as a secondary

298 This was primarily at the expense of nephrectomy, with cases showing significant decline in b

299 Bilateral nephrectomies within the first 3 months of life are asso

300 ients completed successful single-port donor nephrectomy without major complication or open conversio